Q
Quentin M. Anstee
Researcher at Newcastle University
Publications - 335
Citations - 28174
Quentin M. Anstee is an academic researcher from Newcastle University. The author has contributed to research in topics: Fatty liver & Steatohepatitis. The author has an hindex of 62, co-authored 262 publications receiving 16847 citations. Previous affiliations of Quentin M. Anstee include Medical Research Council & University of Newcastle.
Papers
More filters
Journal ArticleDOI
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair M. Younossi,Quentin M. Anstee,Milena Marietti,Timothy Hardy,Timothy Hardy,Linda Henry,Mohammed Eslam,Jacob George,Elisabetta Bugianesi +8 more
TL;DR: The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy.
Journal ArticleDOI
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam,Philip N. Newsome,Shiv Kumar Sarin,Quentin M. Anstee,Giovanni Targher,Manuel Romero-Gómez,Shira Zelber-Sagi,Vincent Wai-Sun Wong,Jean-François Dufour,Jörn M. Schattenberg,Takumi Kawaguchi,Marco Arrese,Luca Valenti,Gamal Shiha,Claudio Tiribelli,Hannele Yki-Järvinen,Jian-Gao Fan,Henning Grønbæk,Yusuf Yilmaz,Helena Cortez-Pinto,Claudia P. Oliveira,Pierre Bedossa,Leon A. Adams,Ming-Hua Zheng,Yasser Fouad,Wah-Kheong Chan,Nahum Méndez-Sánchez,Sang Hoon Ahn,Laurent Castera,Elisabetta Bugianesi,Vlad Ratziu,Jacob George +31 more
TL;DR: A panel of international experts from 22 countries propose a new definition of metabolic-dysfunction-associated fatty liver disease that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases.
Journal ArticleDOI
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
TL;DR: The evidence that suggests NAFLD is a multisystem disease and the factors that might determine interindividual variation in the development and progression of its major hepatic and extrahepatic manifestations are reviewed.
Journal ArticleDOI
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes,Quentin M. Anstee,María Teresa Arias-Loste,Heike Bantel,Stefano Bellentani,Joan Caballería,Massimo Colombo,Antonio Craxì,Javier Crespo,Christopher P. Day,Yuichiro Eguchi,Andreas Geier,Loreta A. Kondili,Daniela C. Kroy,Jeffrey V. Lazarus,Rohit Loomba,Michael P. Manns,Giulio Marchesini,Atsushi Nakajima,Francesco Negro,Salvatore Petta,V. Ratziu,Manuel Romero-Gómez,Arun J. Sanyal,Jörn M. Schattenberg,Frank Tacke,Junko Tanaka,Christian Trautwein,Lai Wei,Stefan Zeuzem,Homie Razavi +30 more
TL;DR: NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed, if obesity and DM continue to increase at current and historical rates.
Journal ArticleDOI
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
Stuart McPherson,Stuart McPherson,Timothy Hardy,E Henderson,Alastair D. Burt,Alastair D. Burt,Christopher P. Day,Christopher P. Day,Quentin M. Anstee,Quentin M. Anstee +9 more
TL;DR: Contrary to current dogma, this study suggests that steatosis can progress to NASH and clinically significant fibrosis.